Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252
Titel:
Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252
Auteur:
Perez, Edith A. Suman, Vera J. Rowland, Kendrith M. Ingle, James N. Salim, Muhammad Loprinzi, Charles L. Flynn, Patrick J. Mailliard, James A. Kardinal, Carl G. Krook, James E. Thrower, Abby R. Visscher, Daniel W. Jenkins, Robert B.